AN2 Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

14.11.24	AN2 Therapeutics to Participate at Upcoming Investor Conferences (Businesswire)
13.11.24	AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline (Businesswire)
17.10.24	AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria (Businesswire)
28.08.24	AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Businesswire)
16.08.24	AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan (Businesswire)
13.08.24	AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights (Businesswire)
08.08.24	AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease (Businesswire)
14.05.24	AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights (Businesswire)
28.03.24	AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights (Businesswire)
12.02.24	AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease (Businesswire)
30.01.24	AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference (Businesswire)
09.11.23	AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights (Businesswire)
06.11.23	AN2 Therapeutics to Present at Upcoming Investor Conferences (Businesswire)
18.10.23	AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease (Businesswire)
11.10.23	AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023 (Businesswire)
26.09.23	AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria (Businesswire)
13.09.23	AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease (Businesswire)
16.08.23	AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock (Businesswire)
10.08.23	AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights (Businesswire)
25.05.23	AN2 Therapeutics to Present at Jefferies Healthcare Conference (Businesswire)
11.05.23	AN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights (Businesswire)
01.05.23	AN2 Therapeutics to Present at JMP Securities Life Sciences Conference (Businesswire)
29.03.23	AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights (Businesswire)
28.02.23	AN2 Therapeutics to Participate in Upcoming Investor Conferences (Businesswire)
31.01.23	AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Roche Hldg G	329.60	1.38 %	K V
Novartis	110.10	1.27 %	K V
CieFinRichemont	170.05	1.19 %	K V
Swiss Life Hldg	920.00	0.68 %	K V
Swiss Re	132.70	0.64 %	K V
Part Grp Hldg	976.40	-0.14 %	K V
Nestle	77.83	-0.26 %	K V
Sika	161.70	-0.40 %	K V
Geberit	616.00	-0.58 %	K V
Alcon	63.40	-0.69 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

AN2 Therapeutics Aktie VALOR 117361169 / ISIN US0373261058

Nachrichten zu AN2 Therapeutics Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten